tbuckley/cabot-search huggingface dataset:
Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
Authors: Maximilian Mossner, Alexandra Stoehr, Johann-Christoph Jann, Florian Nolte, Verena Nowak, Julia Oblaender, Jovita Pressler, Christina Xanthopoulos, Iris Palme, Claudia D Baldus, Torsten Schulze, Tobias Boch, Georgia Metzgeroth, Martin Neumann, Wolf-Karsten Hofmann, Daniel Nowak
Journal: Blood (2015)
P08.62 Salvage chemotherapy with bevacizumab and fotemustine in temozolomide-pretreated patients with recurrent grade III gliomas: a phase II study
Authors: F. Franchino, M. Magistrello
Journal: Neuro-Oncology (2016)

AbstractIntroduction:Fotemustine is a nitrosourea with elevated lipophilic properties, that has shown activity as monotherapy in recurrent grade III gliomas, but few data are available on the association with the antiangiogenic drug bevacizumab.Method:From July 2008 to November 2015 we accrued, in this single arm phase II study, patients with an histological diagnosis of grade III glioma (according to WHO, 2007) at relapse after radiotherapy and/or temozolomide and we treated them with a combination of bevacizumab and fotemustine. The primary endpoint was 6-month progression-free survival (PFS-6), while secondary endpoints were overall survival (OS), disease control rate and toxicity.Results:Forty-six patients with grade III glioma (22 astrocytomas, 10 oligodendrogliomas and 14 oligoastrocytomas, 67% MGMT methylated and 30% 1p/19q codeleted) were enrolled. Median age was 45 years and KPS ≥ 90 in 54%. PFS-6, median PFS and OS were 45%, 5 months and 9 months, respectively. Nineteen patients (41%) had already received prior chemotherapy lines and 35% a second surgery before inclusion into the trial. We observed a 95% disease control rate (response or stable disease on MRI) after the induction phase with a neurological improvement in 40% and steroid reduction or withdrawal in 67%. In a preliminary analysis we didn’t observe significant differences in terms of clinical and/or radiological response rate, in PFS or OS according to MGMT methylation and 1p/19q codeletion status. There was a better clinical improvement in oligodendroglial subtype after induction phase (75% of patients), while no differences emerged in radiological disease control rate, PFS6, PFS or OS compared to astrocitary histotype. Survival rates of the whole cohort were 34% at 1 year, 21% at 2 years, 14% at 3 years, 7% at 4 years and 5% at 5 years. The pattern of progression was focal enhancing in 73% of tumors, diffuse non-enhancing (gliomatosis-like) in 12%, multicentric in 10% and local plus leptomeningeal in 5%.Twenty-two percent of patients discontinued fotemustine for grade 3/4 myelotoxicity. We did not observe any additional toxicity from the combination.Conclusions:The combination of bevacizumab and fotemustine as salvage treatment for grade III gliomas is safe and somewhat active in this heavily pretreated cohort. Further clinical studies should explore alternative regimens of therapy in the different molecular subgroups.
Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Authors: Johannes L. Zakrzewski, Adam A. Kochman, Sidney X. Lu, Theis H. Terwey, Theo D. Kim, Vanessa M. Hubbard, Stephanie J. Muriglan, David Suh, Javier Cabrera-Perez, Radhika Radhakrishnan, Glenn Heller, Juan Carlos Zuniga-Pflucker, Onder Alpdogan, Marcel R.M. van den Brink
Journal: Blood (2005)
immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Authors: E. Cohen, N.F. Saba, B. Gitlitz, R. Haddad, A. Sukari, P. Neupane, J.C. Morris, K. Misiukiewicz, K.L. Manjarrez, G.N. Dietsch, J.K. Bryan, R.M. Hershberg, R.L. Ferris
Journal: Annals of Oncology (2016)
Incidence, Clinical Presentations and Management of Isolated Extramedullary Relapses After Allogeneic Hematopoietic Stem Cell Transplantation for Acute and Chronic Leukemias: An Updated Single-Center Analysis of 612 Patients.
Authors: Dariusz Kata, Miroslaw Markiewicz, Tomasz Czerw, Marek Seweryn, Slawomira Kyrcz-Krzemien
Journal: Blood (2010)
Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?
Authors: J. Evans, J. Bhoday, B. Sizer, P. Tekkis, R. Swift, R. Perez, D. Tait, G. Brown
Journal: Annals of Oncology (2016)
NIMG-14. THE INFLUENCE OF PROTEIN INTAKE ON O-(2-18F-FLUOROETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY (FET-PET) IN GLIOMAS
Authors: Sarah Chehri, Otto Mølby Henriksen, Lisbeth Marner, Mette Christensen, Aida Muhic, Hans Skovgaard Poulsen, Ian Law
Journal: Neuro-Oncology (2016)

FET-PET scanning is used in routine clinical management and evaluation of glioma. The aim of the study was to investigate the impact of prior protein intake on tumour activity and delineation in FET-PET scanning in glioma patients. 6 histologically confirmed high (4) and low grade (2) glioma patients were included in this ongoing prospective study. Subjects were divided into 3 groups: 1 in high-dose protein (HP), 4 in moderate-dose protein (MP) and 1 in no protein (NP). On a Siemens PET/CT scanner a 40 min. dynamic FET-PET scan was repeated with 3-7 days between scans. HP and MP consumed respectively 48g or 24g casein-based protein (Nutricia Nutridrink Compact®) orally an hour before one of the scans. Blood samples were drawn before and after protein intake for determining the plasma amino acid concentration. Volumes of interest were delineated on the 20-40 min 18F-FET PET acquisition co-registered to T1-postgadolinium contrast MRI. The two scans were compared by calculating the absolute change between healthy appearing cortex (B), the maximal and the mean tumour uptake normalized to B (Tmax/B; Tmean/B) and by measuring the biological tumour volume (BTV). The overall FET activity reduction in healthy appearing cortex by protein intake (HP, MP) was 29% [23%; 36%] vs. 1% in NP. Absolute change in FET tumour metrics: Tmax/B: HP=0.82, MP=0.06 [-0.11; 0.18], NP=-0.01. Tmean/B: HP=0.22, MP=0.01 [-0.02; 0.03], NP=-0.02. BTV: HP=6.3mL, MP=0.6mL [-0.1mL; 1.8mL], NP=0.1mL. Protein intake reduces FET activity uptake in healthy appearing brain by 29 %. A slight increase was found in the routine FET-PET tumour metrics after modest protein intake, while high protein intake might not be clinically acceptable. These preliminary results indicate that a FET-PET scanning may be valid after moderate accidental protein intake in clinical routine use. Further results will be presented.
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study
Authors: C. Bergamini, C. Bergamini, D. Cortinovis, S. Fatigoni, M. Cossu Rocca, A. Fabi, A. Iannace, A. Emiliani, M.A. Pessi, C.I. Ripamonti, S. Alfieri, R. Granata, F. Agustoni, P. Bidoli, F. Roila, F. Nolé, F. Macchi, L. Michellini, F. Montanaro, P. Bossi
Journal: Annals of Oncology (2016)
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Authors: Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind
Journal: The Lancet Neurology (2017)
P09.10 The prognostic value of a novel quantitative MGMT promoter methylation score for patients with glioblastoma
Authors: S. J. Han, A. Ravi
Journal: Neuro-Oncology (2017)

Evidence continues to solidify the central role molecular markers play in gliomas. Methylation status of MGMT promoter has been shown as a key marker in glioblastoma, predicting response to temozolomide. Traditional testing of MGMT promoter methylation, performed using a methylation specific PCR, yields a binary result; however it fails to consider the multiple potential methylation sites in MGMT’s promoter region. A novel quantitative bisulfite Sanger DNA sequencing assay evaluates methylation status at each of the 17 potential methylation sites in the promoter, resulting in a methylation score of 0-17. This novel assay was evaluated for its prognostic role in a cohort of 180 consecutive patients undergoing treatment for newly diagnosed glioblastoma from April 2014 to August 2015. All patients received concurrent chemoradiation with temozolomide. Univariate and multivariate models for overall survival were built along with other established prognostic variables such as age, KPS and extent of resection. The methylation score was predictive of overall survival as a linear model. Stratification into partition groups revealed 3 groups (in order of increasing survival): A)Age greater than or equal to 70, B)Age less than 70 and KPS equal to or less than 70 or Age less than 70 and KPS greater than 70 and MGMT score less than or equal to 8 and C)Age less than 70 and KPS greater than 70, and MGMT score greater than 8. Brier score revealed lower predictive error for the methylation score compared to the traditional binary MGMT promoter methylation assessment, suggesting the methylation score is a more reliable model predicting survival. The methylation score, derived from the bisulfite sequencing analysis, provides a quantitative representation of the degree of methylation in the MGMT promoter. Survival models and partitioning support its role as a prognostic marker for overall survival, and the methylation score being superior to the traditional MGMT promoter methylation analysis in predicting survival in patients with newly diagnosed glioblastoma. Prospective validation and comparison to older/newer techniques including next-generation sequencing are warranted.
Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.
Authors: Laura F Newell, Hu Xie, John M. Pagel, Ravinder K Sandhu, Pamela S Becker, Roland B. Walter, Kathleen Shannon Dorcy, Janis L Abkowitz, Frederick R. Appelbaum, Elihu H. Estey
Journal: Blood (2012)
Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion
Authors: Tomokazu Ohishi, Haruka Yoshida, Masamichi Katori, Toshiro Migita, Yukiko Muramatsu, Mao Miyake, Yuichi Ishikawa, Akio Saiura, Shun-ichiro Iemura, Tohru Natsume, Hiroyuki Seimiya
Journal: Cancer Research (2017)

Tankyrase, a PARP that promotes telomere elongation and Wnt/β-catenin signaling, has various binding partners, suggesting that it has as-yet unidentified functions. Here, we report that the tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton and cancer cell invasion, which is closely associated with cancer progression. TNKS1BP1 colocalized with actin filaments and negatively regulated cell invasion. In TNKS1BP1-depleted cells, actin filament dynamics, focal adhesion, and lamellipodia ruffling were increased with activation of the ROCK/LIMK/cofilin pathway. TNKS1BP1 bound the actin-capping protein CapZA2. TNKS1BP1 depletion dissociated CapZA2 from the cytoskeleton, leading to cofilin phosphorylation and enhanced cell invasion. Tankyrase overexpression increased cofilin phosphorylation, dissociated CapZA2 from cytoskeleton, and enhanced cell invasion in a PARP activity-dependent manner. In clinical samples of pancreatic cancer, TNKS1BP1 expression was reduced in invasive regions. We propose that the tankyrase-TNKS1BP1 axis constitutes a posttranslational modulator of cell invasion whose aberration promotes cancer malignancy. Cancer Res; 77(9); 2328-38. ©2017 AACR.
STMC-04. THE UTILITY OF X0-GLIOMA STEM CELL LINES IN UNDERSTANDING OF GLIOMAGENESIS
Authors: Akio Soeda, Deric Park, Toru Iwama
Journal: Neuro-Oncology (2016)

We have established glioma stem cell lines from patients, named X0-series, representing cancer stem cell features, including self-renewal, multipotential differentiation, and recapitulation, both in vitro and in vivo, and even in long-term cultures (A Inagaki et al. BBRC 2007, N Oka et al. BBRC 2007). We have been providing these cell lines to researchers on request, with material transfer agreement, and they have been studied around the world (4 institutions in Japan, 8 in USA, and 5 in Korea). These researchers have independently investigated their original ideas and published their own results, without sharing authorship with us, acknowledging us for providing the cells. By their excellent efforts, fifteen articles have been published; eight are from our laboratory. In these publications, we have indicated that EGF-EGFR-Akt pathway and hypoxia play an important role in glioma stem cell maintenance (A Soeda et al. J Biol Chem. 2008, A Soeda et al. Oncogene 2009), and showed the evidence of glioblastoma heterogeneity (A Soeda et al. Sci Rep. 2015). Q Xie et al. suggested that HGF autocrine loop activated MET signal pathway in glioblastomagenesis (PNAS 2012). J Yin et al. reported the relationship between pigment epithelium-derived factor, EGFRvIII, and glioma stem cell progression (PLOS Biol 2015), whereas X Jin et al. reported that EGFR-Akt-Smad pathway promoted tumorigenesis via ID3 (Cancer Res 2011). Furthermore, other researchers have reported important knowledge about tumor niche (HM Jeon et al. Cancer Res 2014), radiation therapy (RK Kim et al. Cancer Sci. 2013), immunotherapy (HC Tseng et al. J. Cancer 2015), new drug (J Kim et al. Stem Cells Dev. 2015), etc. Here, we summarize the independent results from different laboratories using X0-glioma stem cell lines and discuss the utility of these cell lines in glioma stem cell research.
Normal Gallbladder Ejection Fraction Occurring Unexpectedly Obviates Need for Sincalide Stimulation
Authors: Samir Hadi, Mark Tulchinsky
Journal: Clinical Nuclear Medicine (2017)

A 25-year-old man was referred for chronic right upper quadrant abdominal pain for hepatobiliary scintigraphy to evaluate the gallbladder (GB) function. An unexpected GB contraction with ejection fraction (EF) of 90% was observed during the first hour of baseline imaging. Subsequent stimulation with sincalide produced GB EF of 99%. A similar case previously reported also showed normal unexpected GB EF that predicted similar post–sincalide GB EF. These examples support what should be evident: A normal unexpected GB EF is a sufficient evidence for a normal GB function and should obviate need for sincalide stimulation.
The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial
Authors: Leona M Dowman, Christine F McDonald, Catherine J Hill, Annemarie L Lee, Kathryn Barker, Claire Boote, Ian Glaspole, Nicole S L Goh, Anne M Southcott, Angela T Burge, Rebecca Gillies, Alicia Martin, Anne E Holland
Journal: Thorax (2017)

<h3>Background</h3> Uncertainty exists regarding the clinical relevance of exercise training across the range of interstitial lung diseases (ILDs). <h3>Objective</h3> To establish the impact of exercise training in patients with ILDs of differing aetiology and severity. <h3>Methods</h3> 142 participants with ILD (61 idiopathic pulmonary fibrosis (IPF), 22 asbestosis, 23 connective tissue disease-related ILD (CTD-ILD) and 36 with other aetiologies) were randomised to either 8 weeks of supervised exercise training or usual care. Six-minute walk distance (6MWD), Chronic Respiratory Disease Questionnaire (CRDQ), St George Respiratory Questionnaire IPF-specific version (SGRQ-I) and modified Medical Research Council dyspnoea score were measured at baseline, 9 weeks and 6 months. <h3>Measurements and main results</h3> Exercise training significantly increased 6MWD (25 m, 95% CI 2 to 47 m) and health-related quality of life (CRDQ and SGRQ-I) in people with ILD. Larger improvements in 6MWD, CRDQ, SGRQ-I and dyspnoea occurred in asbestosis and IPF compared with CTD-ILD, but with few significant differences between subgroups. Benefits declined at 6 months except in CTD-ILD. Lower baseline 6MWD and worse baseline symptoms were associated with greater benefit in 6MWD and symptoms following training. Greater gains were seen in those whose exercise prescription was successfully progressed according to the protocol. At 6 months, sustained improvements in 6MWD and symptoms were associated with better baseline lung function and less pulmonary hypertension. <h3>Conclusions</h3> Exercise training is effective in patients across the range of ILDs, with clinically meaningful benefits in asbestosis and IPF. Successful exercise progression maximises improvements and sustained treatment effects favour those with milder disease. <h3>Trial registration number</h3> Results, ACTRN12611000416998.
DDIS-05. TARGETING MESENCHYMAL GLIOBLASTOMA THROUGH INHIBITION OF DIACYLGLYCEROL KINASE ALPHA
Authors: Inan Olmez, Shawn Love
Journal: Neuro-Oncology (2016)

Recent studies have shown that glioblastoma (GBM) can be classified into distinct subtypes based on gene expression signatures: classical, proneural, and mesenchymal. Of these, the mesenchymal subtype is relatively more aggressive and resistant to therapy, and is thought to be a primary driver of recurrence. The diacylglycerol kinase alpha (DGKα) signaling pathway has extensive connections to oncogenic pathways/proteins. Recently, we identified ritanserin, an abandoned serotonin receptor 5-HT2 inhibitor originally developed for schizophrenia, as a novel DGKα inhibitor. Compared to a known DGKα inhibitor, R59022, ritanserin is more potent and has favorable pharmacologic features such as long plasma half-life and known BBB penetration. Based on the TCGA database, we have determined that DGKα expression level is highest in the mesenchymal subtype. DGKα inhibition with ritanserin revealed a significant difference in IC50 values, with a 3-4 fold increase in sensitivity, of all mesenchymal GBM stem cell (GSC) lines tested versus all non-mesenchymal lines. In vivo, daily oral ritanserin increased mice survival significantly with two mesenchymal GSC lines, while there was no survival benefit with a proneural GSC line. With an EMT model, both lung and pancreatic carcinoma cells became more sensitive to ritanserin after the acquisition of mesenchymal phenotype. Ritanserin reduces NF-κB activity significantly and suppresses geranylgeranylation of proteins by inhibiting geranylgeranyltransferase I. Exogenous phosphatidic acid, the DGKα enzymatic product, substantially rescued GBM cells from ritanserin toxicity while exogenous 5-HT2 receptor agonist, 5-hydroxytryptamine, showed a small rescue from ritanserin toxicity. In keeping with its anti-mesenchymal activity, ritanserin functions as a radiosensitizer, with suppression of the DNA damage response and shows significant synergy with radiation. Our work is the first to show in vitro and in vivo that a clinically practical agent has strong preferential toxicity for the mesenchymal GBM subtype, with potential therapeutic implications for GBM and other cancers as well.
OS2.4 Expression and relevance of tumoral and stromal MHC class II in gliomas
Authors: F. Sahm, K. Ochs, L. Bunse, E. Barnea, N. Trautwein, M. Weller, A. von Deimling, A. Admon, W. Wick, M. Platten
Journal: Neuro-Oncology (2016)
One-step, exchange-free, single-balloon-assisted endoscopic ultrasound-guided gastroenterostomy with lumen-apposing metal stent in malignant gastric outlet obstruction
Authors: Ilaria Tarantino, Dario Ligresti, Luca Barresi, Gabriele Curcio, Antonino Granata, Mario Traina
Journal: Endoscopy (2017)

An 81-year-old woman with malignant gastric outlet obstruction due to pancreatic adenocarcinoma ([Fig. 1 a]) was referred to our institute for endoscopic ultrasound (EUS)-guided gastroenterostomy.
Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
Authors: A.S. Berghoff, J. Furtner, G. Widhalm, B. Gatterbauer, U. Dieckmann, P. Birner, R. Bartsch, C. Zielinski, V. Schöpf, M. Preusser
Journal: Annals of Oncology (2016)
ICAM-1(CD54) and Tissue Factor (CD142) Monocytes Expression Among Sickle Cell Anemia Steady-State Children: Association with VCAM-1 and ICAM-1 Soluble and Cytokines Related to Inflamossome and Th17 Response.
Authors: Wendell Vilas Boas, Bruno Antônio Veloso Cerqueira, Angela MD Zanette, Jorge Clarêncio, Daniela Andrade, Marilda Souza Goncalves
Journal: Blood (2009)
Comparison of Liver Iron Concentration Measured by the SQUID Biosusceptometers at Hamburg, Torino and Oakland in Patients with Thalassemia and Sickle Cell Disease.
Authors: Ellen B. Fung, Filomena Longo, Roland Fischer, Rainer Engelhardt, Zahra Pakbaz, Herbert Optiz, Robert L. Fagaly, Hanspeter Nick, Peter Nielsen, Elliott Vichinsky, Antonio Piga, Paul Harmatz
Journal: Blood (2005)
γ-Globin Gene (HBG) Promoter Methylation and Gene Expression Is Affected by the Micro-Environment In Adult but Not Fetal Erythroid Cells
Authors: Donald Lavelle, Yogenthiran Saunthararajah, Nadim Mahmud, Vinzon Ibanez, Maria Armila Ruiz, Kestis Vaitkus, Tatiana Kouznetsova, Joseph DeSimone
Journal: Blood (2010)
Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.
Authors: Jennifer Rhodes, Adam Amsterdam, Karen Ho, Stefan Heinrichs, John P. Kanki, Jennifer E. O’Neil, Alejandro Gutierrez, Keith McKenna, Hui Feng, Mark Fleming, Donna Neuberg, Ilene Galinsky, Richard M. Stone, Nancy Hopkins, A. Thomas Look
Journal: Blood (2006)
Recurrent VAV1 Abnormalities in Angioimmunoblastic T Cell Lymphoma
Authors: Daisuke Komori, Mamiko Sakata-Yanagimoto, Sharna Tanzima Nuhat, Kota Fukumoto, Manabu Fujisawa, Shoko Nishizawa, Kosei Matsue, Koji Izutsu, Naoya Nakamura, Kenichi Yoshida, Seishi Ogawa, Shigeru Chiba
Journal: Blood (2016)